U.S. Solid Tumor Testing Market: Focus on Technology, Cancer Type, Biomarker Type, Application, End User, State Region, and Competitive Landscape - Analysis and Forecast, 2019-2030
Hard copy option is available on any of the options above at an additional charge of $500. Please email us at [email protected] with your request.
Market Report Coverage - U.S. Solid Tumor Testing
Market Segmentation
Abbott Laboratories, Laboratory Corporation of America, Quest Diagnostics Incorporated, Illumina, F. Hoffmann-La Roche, ARUP Laboratories, Bio-Rad Laboratories Inc., Asuragen Inc., Cancer Genetics Inc., Invitae Corporation, NeoGenomics Laboratories, Inc., and QIAGEN N.V
Key Questions Answered:
The term solid tumor refers to abnormal cellular growths, which generally comprise sarcomas, carcinomas, and lymphomas. The current solid tumor testing market is mainly dominated by several diagnostic majors, such as Quest Diagnostics Incorporated, Laboratory Corporation of America, Foundation Medicine, which offer a wide variety of testing services for solid tumors. These testing services ranges from molecular-genetic tests to liquid biopsies for the confirmatory diagnosis of solid tumors. The key players in the product segment include Illumina, Abbott Laboratories and ThermoFisher Scientific, which offer kits for the analysis of solid tumors.
The solid tumor tests are generally based on technologies such as fluorescence in situ hybridization (FISH), immunohistochemistry (INC), bi-directional sanger sequencing, polymerase chain reaction (PCR), next-generation sequencing (NGS), and other technologies. The underlying utility of diagnostic testing for solid tumors is based on the identification of clinically actionable gene mutations, which provide crucial information on diagnosis, prognosis, and theranosis of solid tumors and thereby facilitate clinical work-up, treatment management, and therapeutic selection.
The existing market of solid tumor testing is favored by multiple factors, which include rising government initiatives, increasing incidence of cancer, thereby increasing the utilization of testing technologies to identify the underlying mutations. In addition, an increasing number of product approvals and launches pertaining to U.S. solid tumor testing market will provide a lucrative growth for this market. Moreover, increasing use of biomarkers in cancer profiling is also one of the key driving factors for solid tumor testing market.
Government funding is also one of the major growth factors for the solid tumor testing market, because increasing funding by the government is expected to facilitate research institutes and key players to develop as well as market novel assays useful for the diagnosis of several tumors. Increasing funding will lead to liquidity of the solid tumor market, and thus, companies will develop various testing options for solid tumors to identify the underlying mutations that serve as a possible cause for the disease. All these factors are therefore expected to contribute to the market growth during the forecast period.
Within the research report, the market is segmented on the basis of product type, technology, application, end user, cancer type, biomarker type and region, which highlight value propositions and business models useful for industry leaders and stakeholders. The research also comprises state-level analysis, go-to-market strategies of leading players, future opportunities, among others, to detail the scope and provide a 360-degree coverage of the domain.
Competitive Landscape
Major players, including Laboratory Corporation of America, QIAGEN N.V., Illumina, Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd., Quest Diagnostic Incorporated, and Thermo Fisher Scientific, among others, led the number of synergistic developments (partnerships and alliances) witnessed by the market. On the basis of state, California is expected to retain a leading position throughout the forecast period 2020-2030, followed by Florida. This is a result of the presence of leading industry players in this region, coupled up with the highest prevalence of solid tumors in 2017.
Market Report Coverage - U.S. Solid Tumor Testing
Market Segmentation
- By Product: Kits and Services
- By Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), In Situ Hybridization (ISH), Immunohistochemistry (IHC) and Other Technologies
- By Application: Clinical and Research Segments
- By End User: Hospital, Diagnostic Laboratories and Reference Laboratories, Pharmaceutical and Biotechnology Company, Contract Research Organizations, Academic Research Institutions and Other End Users
- By Cancer Type: Breast Cancer, Colorectal Cancer, Melanoma, Thyroid Cancer, Ovarian Cancer, Prostate Cancer, Lung Cancer, Endometrial Cancer, Brain Cancer, Liver Cancer and Other Cancers
- U.S. – State Specific Stratification
- Rising Incidence of Cancers
- Increasing Adoption of Inorganic Growth Strategies in the Market
- Increasing Research Funding from National Cancer Institute
- Reimbursement Cuts in the U.S.
- High Pricing Pressure
- Expected Implementation of Patient Protection and Affordable Care Act (PPACA) in the U.S.
- Informatics and Technological Innovation for Larger Consumer Base
- Expected Increase in the Adoption of Genetic Testing
Abbott Laboratories, Laboratory Corporation of America, Quest Diagnostics Incorporated, Illumina, F. Hoffmann-La Roche, ARUP Laboratories, Bio-Rad Laboratories Inc., Asuragen Inc., Cancer Genetics Inc., Invitae Corporation, NeoGenomics Laboratories, Inc., and QIAGEN N.V
Key Questions Answered:
- What is solid tumor testing? How have different testing technologies for solid tumor testing evolved over the centuries?
- What are the major market drivers, challenges, and opportunities in the U.S. solid tumor testing market?
- What was the U.S. solid tumor testing market size in terms of revenue in 2019? How is the market expected to evolve in the upcoming years? What is the expected market size in 2030?
- How is each segment of the U.S. solid tumor testing market expected to grow during the forecast period between 2020 to 2030, and what is the revenue expected to be generated by each of the segments by the end of 2030?
- What are the developmental strategies implemented by the key players to sustain in the competitive market?
- What is the growth potential of the solid tumor testing market in several states across the U.S.?
- Which product among the two (kits and services) are offered by key players such as Laboratory Corporation of America, Quest Diagnostics Incorporated, Abbott Laboratories, Illumina Inc., Qiagen N.V., and F. Hoffmann-La Roche Ltd.?
- Which technology was leading the market in 2019 and expected to dominate the market by 2030 and why?
- Which application type was leading the market in 2019 and is expected to dominate the market in 2030 and why?
- Which region dominated the U.S. solid tumor testing market in 2019, and what are the expected trends from each of the regions in the forecast period 2020-2030?
The term solid tumor refers to abnormal cellular growths, which generally comprise sarcomas, carcinomas, and lymphomas. The current solid tumor testing market is mainly dominated by several diagnostic majors, such as Quest Diagnostics Incorporated, Laboratory Corporation of America, Foundation Medicine, which offer a wide variety of testing services for solid tumors. These testing services ranges from molecular-genetic tests to liquid biopsies for the confirmatory diagnosis of solid tumors. The key players in the product segment include Illumina, Abbott Laboratories and ThermoFisher Scientific, which offer kits for the analysis of solid tumors.
The solid tumor tests are generally based on technologies such as fluorescence in situ hybridization (FISH), immunohistochemistry (INC), bi-directional sanger sequencing, polymerase chain reaction (PCR), next-generation sequencing (NGS), and other technologies. The underlying utility of diagnostic testing for solid tumors is based on the identification of clinically actionable gene mutations, which provide crucial information on diagnosis, prognosis, and theranosis of solid tumors and thereby facilitate clinical work-up, treatment management, and therapeutic selection.
The existing market of solid tumor testing is favored by multiple factors, which include rising government initiatives, increasing incidence of cancer, thereby increasing the utilization of testing technologies to identify the underlying mutations. In addition, an increasing number of product approvals and launches pertaining to U.S. solid tumor testing market will provide a lucrative growth for this market. Moreover, increasing use of biomarkers in cancer profiling is also one of the key driving factors for solid tumor testing market.
Government funding is also one of the major growth factors for the solid tumor testing market, because increasing funding by the government is expected to facilitate research institutes and key players to develop as well as market novel assays useful for the diagnosis of several tumors. Increasing funding will lead to liquidity of the solid tumor market, and thus, companies will develop various testing options for solid tumors to identify the underlying mutations that serve as a possible cause for the disease. All these factors are therefore expected to contribute to the market growth during the forecast period.
Within the research report, the market is segmented on the basis of product type, technology, application, end user, cancer type, biomarker type and region, which highlight value propositions and business models useful for industry leaders and stakeholders. The research also comprises state-level analysis, go-to-market strategies of leading players, future opportunities, among others, to detail the scope and provide a 360-degree coverage of the domain.
Competitive Landscape
Major players, including Laboratory Corporation of America, QIAGEN N.V., Illumina, Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd., Quest Diagnostic Incorporated, and Thermo Fisher Scientific, among others, led the number of synergistic developments (partnerships and alliances) witnessed by the market. On the basis of state, California is expected to retain a leading position throughout the forecast period 2020-2030, followed by Florida. This is a result of the presence of leading industry players in this region, coupled up with the highest prevalence of solid tumors in 2017.
EXECUTIVE SUMMARY
1 PRODUCT DEFINITION
1.1 Inclusion and Exclusion
2 MARKET SCOPE
2.1 Scope of Work
2.2 Key Questions Answered in the Report
3 RESEARCH METHODOLOGY
3.1 U.S. Solid Tumors Testing Market: Research Methodology
3.2 Data Sources
3.3 Secondary Data Sources
3.4 Market Estimation Model
3.5 Criteria for Company Profiling
4 MARKET OVERVIEW
4.1 Definition
4.2 Solid Tumor Testing Technologies
4.3 Market Size and Growth Potential, $Million, 2019-2030
4.4 Industry Participants Landscape
5 EPIDEMIOLOGY OF SOLID TUMORS IN U.S.
6 INDUSTRY INSIGHTS
6.1 Regulation of Genetic Tests
6.1.1 FDA Regulation
6.1.2 CMS Regulation
6.2 Reimbursement Scenario
6.2.1 Impact on Laboratory Industry
7 MARKET DYNAMICS
7.1 Market Drivers
7.1.1 Rising Incidence of Cancers
7.1.2 Decreasing Cost of Sequencing
7.1.3 Increasing Adoption of Inorganic Growth Strategies in the Market
7.1.4 Increasing Research Funding from National Cancer Institute
7.1.5 Expected Increase in Adoption of Genetic Testing
7.2 Restraints
7.2.1 Reimbursement Cuts in the U.S.
7.2.2 Expected Implementation of Patient Protection and Affordable Care Act in the U.S.
7.2.3 High Pricing Pressure
7.3 U.S. Market Opportunities
7.3.1 Informatics and Technological Innovation for Larger Consumer Base
7.3.2 Mushrooming Direct-to-Consumer (DTC) Testing Services Market
8 COMPETITIVE LANDSCAPE
8.1 Key Strategies and Developments
8.1.1 Synergistic Activities
8.1.2 Approvals
8.1.3 Product Launches, Enhancements and Expansion
8.1.4 Acquisitions and Mergers
8.2 Product Scenario
8.3 Funding Scenario
8.4 Market Share Analysis
8.5 Growth Share Analysis (Opportunity Mapping)
8.5.1 By Company
8.5.2 By Technology
8.5.3 By Application
8.5.4 By Cancer Type
9 U.S. SOLID TUMOR TESTING MARKET (BY TECHNOLOGY)
9.1 Overview
9.2 Next-Generation Sequencing
9.3 In Situ Hybridization
9.4 Polymerase Chain Reaction
9.5 Immunohistochemistry
9.6 Other Technologies
10 U.S. SOLID TUMOR TESTING MARKET (BY CANCER TYPE)
10.1 Overview
10.2 Breast Cancer
10.3 Prostate Cancer
10.4 Colorectal Cancer
10.5 Lung Cancer
10.6 Melanoma
10.7 Endometrial Cancer
10.8 Thyroid Cancer
10.9 Brain Cancer
10.10 Ovarian Cancer
10.11 Liver Cancer
10.12 Other Cancer Types
11 U.S. SOLID TUMOR TESTING MARKET (BY TYPE OF BIOMARKER)
11.1 Overview
11.2 Genetic Biomarkers
11.3 Protein Biomarkers
11.4 Other Biomarkers
12 U.S. SOLID TUMOR TESTING MARKET (BY APPLICATION)
12.1 Overview
12.2 Clinical
12.3 Research
13 U.S. SOLID TUMOR TESTING MARKET (BY END USER)
13.1 Overview
13.2 Hospitals, Diagnostic Laboratories, and Reference Laboratories
13.3 Pharmaceutical and Biotechnology Companies
13.4 Contract Research Organizations
13.5 Academic Research Institutions
13.6 Other End Users
14 U.S. SOLID TUMOR TESTING MARKET (BY STATE REGION)
14.1 Overview
14.2 The South U.S.
14.3 The Midwest U.S.
14.4 The Mid-Atlantic U.S.
14.5 The West U.S.
14.6 The Southwest U.S.
14.7 New England
15 COMPANY PROFILES
15.1 Overview
15.2 Abbott Laboratories
15.2.1 Company Overview
15.2.2 Role of Abbott Laboratories in the U.S. Solid Tumor Testing Market
15.2.3 Financials
15.2.4 Key Insights About Financial Health of the Company
15.2.5 SWOT Analysis
15.3 Illumina, Inc.
15.3.1 Company Overview
15.3.2 Role of Illumina, Inc. in the U.S. Solid Tumor Testing Market
15.3.3 Financials
15.3.4 Key Insights About Financial Health of the Company
15.3.5 SWOT Analysis
15.4 F. Hoffmann-La Roche Ltd.
15.4.1 Company Overview
15.4.2 Role of F. Hoffmann-La Roche Ltd in the U.S. Solid Tumor Testing Market
15.4.3 Financials
15.4.4 Key Insights About Financial Health of the Company
15.4.5 SWOT Analysis
15.5 Bio-Rad Laboratories, Inc.
15.5.1 Company Overview
15.5.2 Role of Bio-Rad Laboratories, Inc. in the U.S. Solid Tumor Testing Market
15.5.3 Financials
15.5.4 Key Insights About Financial Health of the Company
15.5.5 SWOT Analysis
15.6 ASURAGEN, INC.
15.6.1 Company Overview
15.6.2 Role of ASURAGEN, INC. in the U.S. Solid Tumor Testing Market
15.6.3 SWOT Analysis
15.7 Cancer Genetics Inc.
15.7.1 Company Overview
15.7.2 Role of Cancer Genetics Inc.in the U.S. Solid Tumor Testing Market
15.7.3 Financials
15.7.4 Key Insights About Financial Health of the Company
15.7.5 SWOT Analysis
15.8 QIAGEN N.V.*
15.8.1 Company Overview
15.8.2 Role of QIAGEN N.V. in the U.S. Solid Tumor Testing Market
15.8.3 Financials
15.8.4 Key Insights about Financial Health of the Company
15.8.5 SWOT Analysis
15.9 Quest Diagnostics Incorporated
15.9.1 Company Overview
15.9.2 Role of Quest Diagnostics Limited in the U.S. Solid Tumor Testing Market
15.9.3 Financials
15.9.4 SWOT Analysis
15.10 ARUP Laboratories
15.10.1 Company Overview
15.10.2 Role of ARUP Laboratories in the U.S. Solid Tumor Testing Market
15.10.3 SWOT Analysis
15.11 Invivoscribe, Inc.
15.11.1 Company Overview
15.11.2 Role of Invivoscribe, Inc. in the U.S. Solid Tumor Testing Market
15.11.3 SWOT Analysis
15.12 NeoGenomics Laboratories, Inc.
15.12.1 Company Overview
15.12.2 Role of NeoGenomics Laboratories, Inc. in the U.S. Solid Tumor Testing Market
15.12.3 Financials
15.12.4 Key Insights About Financial Health of the Company
15.12.5 SWOT Analysis
15.13 Invitae Corporation
15.13.1 Company Overview
15.13.2 Role of Invitae Corporation, Inc. in the U.S. Solid Tumor testing Market
15.13.3 Financials
15.13.4 Key Insights About Financial Health of the Company
15.13.5 SWOT Analysis
15.14 Opko Health
15.14.1 Company Overview
15.14.2 Role of Opko Health, Inc. in the U.S. Solid Tumor Testing Market
15.14.3 Financials
15.14.4 Key Insights About Financial Health of the Company
15.14.5 SWOT Analysis
15.15 Laboratory Corporation of America Holdings
15.15.1 Company Overview
15.15.2 Role of Laboratory Corporation of America Holdings in the U.S. Solid Tumor Testing Market
15.15.3 Financials
15.15.4 SWOT Analysis
15.16 OmniSeq
15.16.1 Company Overview
15.16.2 Role of OmniSeq in the U.S. Solid Tumor Testing Market
15.16.3 SWOT Analysis
15.17 Nanostring Technologies
15.17.1 Company Overview
15.17.2 Role of Nanostring Technologies in the U.S. Solid Tumor Testing Market
15.17.3 Financials
15.17.4 SWOT Analysis
15.18 Guardant Health
15.18.1 Company Overview
15.18.2 Role of Guardant Health in the U.S. Solid Tumor Testing Market
15.18.3 Financials
15.18.4 SWOT Analysis
15.19 Personal Genome Diagnostics
15.19.1 Company Overview
15.19.2 Role of Personal Genome Diagnostics in the U.S. Solid Tumor Testing Market
15.19.3 SWOT Analysis
15.20 HTG Molecular Diagnostics
15.20.1 Company Overview
15.20.2 Role of HTG Molecular Diagnostics in the U.S. Solid Tumor Testing Market
15.20.3 Financials
15.20.4 SWOT Analysis
15.21 Caris Life Sciences
15.21.1 Company Overview
15.21.2 Role Caris Life Sciences in the U.S Solid Tumor Testing Market
15.21.3 SWOT Analysis
15.22 Genomic Testing Cooperative
15.22.1 Company Overview
15.22.2 Role of Genome Testing Cooperative in the U.S Solid Tumor Testing Market
15.22.3 SWOT Analysis
15.23 ArcherDX, Inc.
15.23.1 Company Overview
15.23.2 Role of ArcherDX, Inc. in the U.S Solid Tumor Testing Market
15.23.3 SWOT Analysis
1 PRODUCT DEFINITION
1.1 Inclusion and Exclusion
2 MARKET SCOPE
2.1 Scope of Work
2.2 Key Questions Answered in the Report
3 RESEARCH METHODOLOGY
3.1 U.S. Solid Tumors Testing Market: Research Methodology
3.2 Data Sources
3.3 Secondary Data Sources
3.4 Market Estimation Model
3.5 Criteria for Company Profiling
4 MARKET OVERVIEW
4.1 Definition
4.2 Solid Tumor Testing Technologies
4.3 Market Size and Growth Potential, $Million, 2019-2030
4.4 Industry Participants Landscape
5 EPIDEMIOLOGY OF SOLID TUMORS IN U.S.
6 INDUSTRY INSIGHTS
6.1 Regulation of Genetic Tests
6.1.1 FDA Regulation
6.1.2 CMS Regulation
6.2 Reimbursement Scenario
6.2.1 Impact on Laboratory Industry
7 MARKET DYNAMICS
7.1 Market Drivers
7.1.1 Rising Incidence of Cancers
7.1.2 Decreasing Cost of Sequencing
7.1.3 Increasing Adoption of Inorganic Growth Strategies in the Market
7.1.4 Increasing Research Funding from National Cancer Institute
7.1.5 Expected Increase in Adoption of Genetic Testing
7.2 Restraints
7.2.1 Reimbursement Cuts in the U.S.
7.2.2 Expected Implementation of Patient Protection and Affordable Care Act in the U.S.
7.2.3 High Pricing Pressure
7.3 U.S. Market Opportunities
7.3.1 Informatics and Technological Innovation for Larger Consumer Base
7.3.2 Mushrooming Direct-to-Consumer (DTC) Testing Services Market
8 COMPETITIVE LANDSCAPE
8.1 Key Strategies and Developments
8.1.1 Synergistic Activities
8.1.2 Approvals
8.1.3 Product Launches, Enhancements and Expansion
8.1.4 Acquisitions and Mergers
8.2 Product Scenario
8.3 Funding Scenario
8.4 Market Share Analysis
8.5 Growth Share Analysis (Opportunity Mapping)
8.5.1 By Company
8.5.2 By Technology
8.5.3 By Application
8.5.4 By Cancer Type
9 U.S. SOLID TUMOR TESTING MARKET (BY TECHNOLOGY)
9.1 Overview
9.2 Next-Generation Sequencing
9.3 In Situ Hybridization
9.4 Polymerase Chain Reaction
9.5 Immunohistochemistry
9.6 Other Technologies
10 U.S. SOLID TUMOR TESTING MARKET (BY CANCER TYPE)
10.1 Overview
10.2 Breast Cancer
10.3 Prostate Cancer
10.4 Colorectal Cancer
10.5 Lung Cancer
10.6 Melanoma
10.7 Endometrial Cancer
10.8 Thyroid Cancer
10.9 Brain Cancer
10.10 Ovarian Cancer
10.11 Liver Cancer
10.12 Other Cancer Types
11 U.S. SOLID TUMOR TESTING MARKET (BY TYPE OF BIOMARKER)
11.1 Overview
11.2 Genetic Biomarkers
11.3 Protein Biomarkers
11.4 Other Biomarkers
12 U.S. SOLID TUMOR TESTING MARKET (BY APPLICATION)
12.1 Overview
12.2 Clinical
12.3 Research
13 U.S. SOLID TUMOR TESTING MARKET (BY END USER)
13.1 Overview
13.2 Hospitals, Diagnostic Laboratories, and Reference Laboratories
13.3 Pharmaceutical and Biotechnology Companies
13.4 Contract Research Organizations
13.5 Academic Research Institutions
13.6 Other End Users
14 U.S. SOLID TUMOR TESTING MARKET (BY STATE REGION)
14.1 Overview
14.2 The South U.S.
14.3 The Midwest U.S.
14.4 The Mid-Atlantic U.S.
14.5 The West U.S.
14.6 The Southwest U.S.
14.7 New England
15 COMPANY PROFILES
15.1 Overview
15.2 Abbott Laboratories
15.2.1 Company Overview
15.2.2 Role of Abbott Laboratories in the U.S. Solid Tumor Testing Market
15.2.3 Financials
15.2.4 Key Insights About Financial Health of the Company
15.2.5 SWOT Analysis
15.3 Illumina, Inc.
15.3.1 Company Overview
15.3.2 Role of Illumina, Inc. in the U.S. Solid Tumor Testing Market
15.3.3 Financials
15.3.4 Key Insights About Financial Health of the Company
15.3.5 SWOT Analysis
15.4 F. Hoffmann-La Roche Ltd.
15.4.1 Company Overview
15.4.2 Role of F. Hoffmann-La Roche Ltd in the U.S. Solid Tumor Testing Market
15.4.3 Financials
15.4.4 Key Insights About Financial Health of the Company
15.4.5 SWOT Analysis
15.5 Bio-Rad Laboratories, Inc.
15.5.1 Company Overview
15.5.2 Role of Bio-Rad Laboratories, Inc. in the U.S. Solid Tumor Testing Market
15.5.3 Financials
15.5.4 Key Insights About Financial Health of the Company
15.5.5 SWOT Analysis
15.6 ASURAGEN, INC.
15.6.1 Company Overview
15.6.2 Role of ASURAGEN, INC. in the U.S. Solid Tumor Testing Market
15.6.3 SWOT Analysis
15.7 Cancer Genetics Inc.
15.7.1 Company Overview
15.7.2 Role of Cancer Genetics Inc.in the U.S. Solid Tumor Testing Market
15.7.3 Financials
15.7.4 Key Insights About Financial Health of the Company
15.7.5 SWOT Analysis
15.8 QIAGEN N.V.*
15.8.1 Company Overview
15.8.2 Role of QIAGEN N.V. in the U.S. Solid Tumor Testing Market
15.8.3 Financials
15.8.4 Key Insights about Financial Health of the Company
15.8.5 SWOT Analysis
15.9 Quest Diagnostics Incorporated
15.9.1 Company Overview
15.9.2 Role of Quest Diagnostics Limited in the U.S. Solid Tumor Testing Market
15.9.3 Financials
15.9.4 SWOT Analysis
15.10 ARUP Laboratories
15.10.1 Company Overview
15.10.2 Role of ARUP Laboratories in the U.S. Solid Tumor Testing Market
15.10.3 SWOT Analysis
15.11 Invivoscribe, Inc.
15.11.1 Company Overview
15.11.2 Role of Invivoscribe, Inc. in the U.S. Solid Tumor Testing Market
15.11.3 SWOT Analysis
15.12 NeoGenomics Laboratories, Inc.
15.12.1 Company Overview
15.12.2 Role of NeoGenomics Laboratories, Inc. in the U.S. Solid Tumor Testing Market
15.12.3 Financials
15.12.4 Key Insights About Financial Health of the Company
15.12.5 SWOT Analysis
15.13 Invitae Corporation
15.13.1 Company Overview
15.13.2 Role of Invitae Corporation, Inc. in the U.S. Solid Tumor testing Market
15.13.3 Financials
15.13.4 Key Insights About Financial Health of the Company
15.13.5 SWOT Analysis
15.14 Opko Health
15.14.1 Company Overview
15.14.2 Role of Opko Health, Inc. in the U.S. Solid Tumor Testing Market
15.14.3 Financials
15.14.4 Key Insights About Financial Health of the Company
15.14.5 SWOT Analysis
15.15 Laboratory Corporation of America Holdings
15.15.1 Company Overview
15.15.2 Role of Laboratory Corporation of America Holdings in the U.S. Solid Tumor Testing Market
15.15.3 Financials
15.15.4 SWOT Analysis
15.16 OmniSeq
15.16.1 Company Overview
15.16.2 Role of OmniSeq in the U.S. Solid Tumor Testing Market
15.16.3 SWOT Analysis
15.17 Nanostring Technologies
15.17.1 Company Overview
15.17.2 Role of Nanostring Technologies in the U.S. Solid Tumor Testing Market
15.17.3 Financials
15.17.4 SWOT Analysis
15.18 Guardant Health
15.18.1 Company Overview
15.18.2 Role of Guardant Health in the U.S. Solid Tumor Testing Market
15.18.3 Financials
15.18.4 SWOT Analysis
15.19 Personal Genome Diagnostics
15.19.1 Company Overview
15.19.2 Role of Personal Genome Diagnostics in the U.S. Solid Tumor Testing Market
15.19.3 SWOT Analysis
15.20 HTG Molecular Diagnostics
15.20.1 Company Overview
15.20.2 Role of HTG Molecular Diagnostics in the U.S. Solid Tumor Testing Market
15.20.3 Financials
15.20.4 SWOT Analysis
15.21 Caris Life Sciences
15.21.1 Company Overview
15.21.2 Role Caris Life Sciences in the U.S Solid Tumor Testing Market
15.21.3 SWOT Analysis
15.22 Genomic Testing Cooperative
15.22.1 Company Overview
15.22.2 Role of Genome Testing Cooperative in the U.S Solid Tumor Testing Market
15.22.3 SWOT Analysis
15.23 ArcherDX, Inc.
15.23.1 Company Overview
15.23.2 Role of ArcherDX, Inc. in the U.S Solid Tumor Testing Market
15.23.3 SWOT Analysis
LIST OF TABLES
Table 4.1: Solid Tumor Testing Technologies for Clinical Laboratories
Table 4.2: Technological Trends in Solid Tumor Testing Market
Table 4.3: Industry Participants Landscape in the U.S Solid Tumor Testing Market
Table 6.1: Examples of New CPT Codes Under the CMS
Table 6.2: New Payment Amounts for ADLTs
Table 7.1: Consolidated Variations in Medicaid & Medicare Revenues Reported by U.S. Majors as Per PAMA
Table 8.1: Market Players With Key Product Listing
Table 8.2: Cancer Moonshot Initiative Partners
Table 11.1: FDA-Approved Stratification Biomarkers for Targeted Therapy in Oncology
Table 4.1: Solid Tumor Testing Technologies for Clinical Laboratories
Table 4.2: Technological Trends in Solid Tumor Testing Market
Table 4.3: Industry Participants Landscape in the U.S Solid Tumor Testing Market
Table 6.1: Examples of New CPT Codes Under the CMS
Table 6.2: New Payment Amounts for ADLTs
Table 7.1: Consolidated Variations in Medicaid & Medicare Revenues Reported by U.S. Majors as Per PAMA
Table 8.1: Market Players With Key Product Listing
Table 8.2: Cancer Moonshot Initiative Partners
Table 11.1: FDA-Approved Stratification Biomarkers for Targeted Therapy in Oncology
LIST OF FIGURES
Figure 1: NCI Fiscal Budget Year on Year, 2013-2018
Figure 2: Impact Analysis of Market Drivers and Market Challenges on the U.S. Solid Tumor Testing Market
Figure 3: U.S. Solid Tumor Testing Market (by Technology), $Million, 2019 and 2030
Figure 4: U.S. Solid Tumor Testing Market (by Cancer Type), $Million, 2019 and 2030
Figure 5: U.S. Solid Tumor Testing Market (by Biomarker Type), $Million, 2019 and 2030
Figure 6: U.S. Solid Tumor Testing Market (by Application), $Million, 2019 and 2030
Figure 7: U.S. Solid Tumor Testing Market (by End User), $Million, 2019 and 2030
Figure 8: Top 5 Contributing States to the U.S. Solid Tumor Testing Market
Figure 2.1: U.S. Solid Tumor Testing Market Segmentation
Figure 3.1: U.S. Solid Tumor Testing Market Research Methodology
Figure 3.2: Primary Research Methodology
Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
Figure 4.1: U.S. Solid Tumor Testing Market 2019-2030
Figure 5.1: Type of Solid Tumors
Figure 5.2: Estimated Percent of New Cancer Cases (by Sex), United States, 2020
Figure 5.3: Expected Cancers Cases in the U.S. (by State), 2020
Figure 5.4: Relative Number of Expected Cancers Cases (by State), 2020
Figure 5.5: Relative Percent of Expected Cancers Cases (by Region), 2020
Figure 5.6: Prevalence of Different Cancers Across the U.S. (2013-2017) *
Figure 7.1: Market Dynamics of U.S. Solid Tumor Testing Market
Figure 7.2: Cancer Cases Projections, 2015-2020
Figure 7.3: Decreasing Cost and Increasing Output (TB) of Genome Sequencing (2009-2025)
Figure 7.4: Synergistic Activities, 2017-2019
Figure 7.5: SBIR and STTR Grants and Contract Funding, 2008-2018
Figure 7.6: NCI Fiscal Budget Year on Year, 2013-2018
Figure 7.7: Reimbursement Cuts Adopted for Oncology Testing, as per PAMA Revisions
Figure 8.1: Share of Key Developments and Strategies, January 2017-December 2019
Figure 8.2: Synergistic Activities Share (by Company), January 2017-December 2019
Figure 8.3: Approvals Share (by Company), January 2017-December 2019
Figure 8.4: Product Launches and Expansion Share (by Company), January 2017-December 2019
Figure 8.5: Acquisitions and Mergers Share (by Company), January 2017-December 2019
Figure 8.6: NCI Budget Allocation, FY2015-FY2018
Figure 8.7: Fund Allocation for Cancer Moonshot Program
Figure 8.8: Market Share Analysis for the U.S. Solid Tumor Testing Market, 2019
Figure 8.9: Growth Share Matrix for U.S. Solid Tumor Testing Market (by Company), 2019
Figure 8.10: Growth Share Matrix for U.S. Solid Tumor Testing Market (by Technology), 2019
Figure 8.11: Growth Share Matrix for U.S. Solid Tumor Testing Market (by Application), 2019
Figure 8.12: Growth Share Matrix for U.S Solid Tumor Testing Market (by Cancer Type), 2019
Figure 9.1: U.S. Solid Tumor Testing Market (by Technology), 2019-2030
Figure 9.2: U.S. Solid Tumor Testing Market (for NGS), 2019-2030
Figure 9.3: U.S. Solid Tumor Testing Market (for Type of NGS Sequencing), 2019-2030
Figure 9.4: U.S. Solid Tumor Testing Market (for ISH), 2019-2030
Figure 9.5: U.S. Solid Tumor Testing Market (for PCR), 2019-2030
Figure 9.6: U.S. Solid Tumor Testing Market (for IHC), 2019-2030
Figure 9.7: U.S. Solid Tumor Testing Market (for Other Technologies), 2019-2030
Figure 10.1: Economic Burden of Major Cancer Types on the U.S. Economy, 2010-2018
Figure 10.2: U.S. Solid Tumor Testing Market (by Cancer Type), 2019-2030
Figure 10.3: Prevalence of Breast Cancer in U.S., 2013-2017
Figure 10.4: U.S. Solid Tumor Testing Market (for Breast Cancer), 2019-2030
Figure 10.5: Total Market Size for U.S. Solid Tumor Testing Market (for Breast Cancer, by Technology), 2019 and 2030
Figure 10.6: Prevalence of Prostate Cancer in U.S., 2013-2017
Figure 10.7: U.S. Solid Tumor Testing Market (for Prostate Cancer), 2019-2030
Figure 10.8: Total Market Size for U.S. Solid Tumor Testing Market (for Prostate Cancer, by Technology), 2019 and 2030
Figure 10.9: Prevalence of Colorectal Cancer in U.S., 2013-2017
Figure 10.10: U.S. Solid Tumor Testing Market (for Colorectal Cancer), 2019-2030
Figure 10.11: Total Market Size for U.S. Solid Tumor Testing Market (for Colorectal Cancer, by Technology), 2019 and 2030
Figure 10.12: Prevalence of Lung Cancer in U.S., 2013-2017
Figure 10.13: U.S. Solid Tumor Testing Market (for Lung Cancer), 2019-2030
Figure 10.14: Total Market Size for U.S. Solid Tumor Testing Market (for Lung Cancer, by Technology), 2019 and 2030
Figure 10.15: Prevalence of Melanoma in U.S., 2013-2017
Figure 10.16: U.S. Solid Tumor Testing Market (for Melanoma), 2019-2030
Figure 10.17: Total Market Size for U.S. Solid Tumor Testing Market (for Melanoma, by Technology), 2019 and 2030
Figure 10.18: Prevalence of Endometrial Cancer in U.S., 2013-2017
Figure 10.19: U.S. Solid Tumor Testing Market (for Endometrial Cancer), 2019-2030
Figure 10.20: Total Market Size for U.S. Solid Tumor Testing Market (for Endometrial Cancer, by Technology), 2019 and 2030
Figure 10.21: Prevalence of Thyroid Cancer in U.S., 2013-2017
Figure 10.22: U.S. Solid Tumor Testing Market (for Thyroid Cancer), 2019-2030
Figure 10.23: Total Market Size for U.S. Solid Tumor Testing Market (for Thyroid Cancer, by Technology), 2019 and 2030
Figure 10.24: Prevalence of Brain Cancer in U.S., 2013-2017
Figure 10.25: U.S. Solid Tumor Testing Market (for Brain Cancer), 2019-2030
Figure 10.26: Total Market Size for U.S. Solid Tumor Testing Market (for Brain Cancer, by Technology), 2019 and 2030
Figure 10.27: Prevalence of Ovarian Cancer in U.S., 2013-2017
Figure 10.28: U.S. Solid Tumor Testing Market (for Ovarian Cancer), 2019-2030
Figure 10.29: Total Market Size for U.S. Solid Tumor Testing Market (for Ovarian Cancer, by Technology), 2019 and 2030
Figure 10.30: Prevalence of Liver Cancer in U.S., 2013-2017
Figure 10.31: U.S. Solid Tumor Testing Market (for Liver Cancer), 2019-2030
Figure 10.32: Total Market Size for U.S. Solid Tumor Testing Market (for Liver Cancer, by Technology), 2019 and 2030
Figure 10.33: U.S. Solid Tumor Testing Market (for Other Cancer Types), 2019-2030
Figure 10.34: Total Market Size for U.S. Solid Tumor Testing Market (for Other Cancer Types, by Technology), 2019 and 2030
Figure 11.1: U.S. Solid Tumor Testing Market (by Type of Biomarker), 2019-2030
Figure 11.2: Technologies and Data Types for Genetic Biomarker Discovery
Figure 11.3: U.S. Solid Tumor Testing Market (for Genetic Biomarkers), 2019-2030
Figure 11.4: Technologies and Data Types for Protein Biomarker Discovery
Figure 11.5: U.S. Solid Tumor Testing Market (for Protein Biomarkers), 2019-2030
Figure 11.6: U.S. Solid Tumor Testing Market (for Other Biomarkers), 2019-2030
Figure 12.1: U.S. Solid Tumor Testing Market (by Application), 2019-2030
Figure 12.2: U.S. Solid Tumor Testing Market (for Clinical Applications), 2019-2030
Figure 12.3: U.S. Solid Tumor Testing Market (for Types of Clinical Applications), 2019-2030
Figure 12.4: U.S. Solid Tumor Testing Market (for Research Applications), 2019-2030
Figure 12.5: U.S. Solid Tumor Testing Market (for Types of Research Applications), 2019-2030
Figure 13.1: U.S. Solid Tumor Testing Market (by End User), 2019-2030
Figure 13.2: U.S. Solid Tumor Testing Market (for Hospitals, Diagnostic Laboratories, and Reference Laboratories), 2019-2030
Figure 13.3: U.S. Solid Tumor Testing Market (for Pharmaceutical and Biotechnology Companies), 2019-2030
Figure 13.4: U.S. Solid Tumor Testing Market (for Contract Research Organization), 2019-2030
Figure 13.5: U.S. Solid Tumor Testing Market (for Academic Research Institutions), 2019-2030
Figure 13.6: U.S. Solid Tumor Testing Market (for Other End Users), 2019-2030
Figure 14.1: U.S. Solid Tumor Testing Market (by State Region), 2019-2030
Figure 14.2: Growth in Top 5 States in the U.S. Solid Tumor Testing Market, 2019-2030
Figure 14.3: The South U.S. Solid Tumor Testing Market, 2019-2030
Figure 14.4: The South U.S. Solid Tumor Testing Market (by State), 2019, 2025, and 2030
Figure 14.5: The Midwest U.S. Solid Tumor Testing Market, 2019-2030
Figure 14.6: The Midwest U.S. Solid Tumor Testing Market (by State), 2019, 2025, and 2030
Figure 14.7: The Mid-Atlantic U.S. Solid Tumor Testing Market, 2019-2030
Figure 14.8: The Mid-Atlantic U.S. Solid Tumor Testing Market (by State), 2019, 2025, and 2030
Figure 14.9: The West U.S. Solid Tumor Testing Market, 2019-2030
Figure 14.10: The West U.S. Solid Tumor Testing Market (by State), 2019, 2025, and 2030
Figure 14.11: The Southwest U.S. Solid Tumor Testing Market, 2019-2030
Figure 14.12: The Southwest U.S. Solid Tumor Testing Market (by State), 2019, 2025, and 2030
Figure 14.13: New England Solid Tumor Testing Market, 2019-2030
Figure 15.1: Total Number of Companies Profiled
Figure 15.2: Abbott Laboratories: Portfolio
Figure 15.3: Abbott Laboratories: Overall Financials, 2017-2019
Figure 15.4: Abbott Laboratories: Revenue (by Segment), 2017-2019
Figure 15.5: Abbott Laboratories: Revenue Split for Diagnostics, 2017-2019
Figure 15.6: Abbott Laboratories: Revenue (by Region), 2017-2019
Figure 15.7: Abbott Laboratories: R&D Expenditure, 2017-2019
Figure 15.8: Abbott Laboratories: SWOT Analysis
Figure 15.9: Illumina, Inc.: Portfolio
Figure 15.10: Illumina, Inc.: Overall Financials, 2017-2019
Figure 15.11: Illumina, Inc.: Revenue (by Segment), 2017-2019
Figure 15.12: Illumina, Inc.: Revenue (by Region), 2017-2019
Figure 15.13: Illumina, Inc.: R&D Expenditure, 2017-2019
Figure 15.14: Illumina, Inc.: SWOT Analysis
Figure 15.15: F. Hoffmann-La Roche Ltd: Portfolio
Figure 15.16: F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019
Figure 15.17: F. Hoffmann-La Roche Ltd: Sales (by Segment), 2017-2019
Figure 15.18: F. Hoffmann-La Roche Ltd: Sales (by Region), 2017-2019
Figure 15.19: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2017-2019
Figure 15.20: F. Hoffmann-La Roche: SWOT Analysis
Figure 15.21: Bio-Rad Laboratories, Inc.: Portfolio
Figure 15.22: Bio-Rad Laboratories, Inc.: Overall Financials, 2017-2019
Figure 15.23: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2017-2019
Figure 15.24: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2017-2019
Figure 15.25: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2017-2019
Figure 15.26: Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 15.27: ASURAGEN, INC.: Portfolio
Figure 15.28: ASURAGEN, INC.: SWOT Analysis
Figure 15.29: Cancer Genetics Inc.: Portfolio
Figure 15.30: Cancer Genetics Inc.: Overall Financials, 2016-2018
Figure 15.31: Cancer Genetics Inc.: Sales (by Segment), 2016-2018
Figure 15.32: Cancer Genetics Inc.: Sales (by Region), 2016-2018
Figure 15.33: Cancer Genetics Inc.: R&D Expenditure, 2016-2018
Figure 15.34: Cancer Genetics Inc.: SWOT Analysis
Figure 15.35: QIAGEN N.V.: Portfolio
Figure 15.36: QIAGEN N.V.: Overall Financials, 2017-2019
Figure 15.37: QIAGEN N.V.: Revenue (by Segment), 2017-2019
Figure 15.38: QIAGEN N.V.: Revenue (by Region), 2017-2019
Figure 15.39: QIAGEN N.V.: R&D Expenditure, 2017-2019
Figure 15.40: QIAGEN N.V.: SWOT Analysis
Figure 15.41: Quest Diagnostics Incorporated: Portfolio
Figure 15.42: Quest Diagnostics Incorporated: Overall Financials, 2017-2019
Figure 15.43: Quest Diagnostics Incorporated: Revenue (by Business Segment), 2017-2019
Figure 15.44: Quest Diagnostics Incorporated: SWOT Analysis
Figure 15.45: ARUP Laboratories: Portfolio
Figure 15.46: ARUP Laboratories: SWOT Analysis
Figure 15.47: Invivoscribe, Inc.: Portfolio
Figure 15.48: Invivoscribe, Inc.: SWOT Analysis
Figure 15.49: NeoGenomics Laboratories, Inc.: Portfolio
Figure 15.50: NeoGenomics Laboratories, Inc.: Overall Financials, 2017-2019
Figure 15.51: NeoGenomics Laboratories, Inc.: Revenue (by Segment), 2017-2019
Figure 15.52: NeoGenomics Laboratories, Inc.: R&D Expenditure, 2017-2019
Figure 15.53: NeoGenomics Laboratories, Inc.: SWOT Analysis
Figure 15.54: Invitae Corporation: Portfolio
Figure 15.55: Invitae Corporation: Overall Financials, 2017-2019
Figure 15.56: Invitae Corporation: Revenue (by Segment), 2017-2019
Figure 15.57: Invitae Corporation: Revenue (by Geography), 2017-2019
Figure 15.58: Invitae Corporation: R&D Expenditure, 2017-2019
Figure 15.59: Invitae Corporation: SWOT Analysis
Figure 15.60: Opko Health: Portfolio
Figure 15.61: Opko Health: Overall Financials, 2017-2019
Figure 15.62: Opko Health: Revenue (by Segment), 2017-2019
Figure 15.63: Opko Health: Revenue (by Region), 2017-2019
Figure 15.64: Opko Health: R&D Expenditure, 2017-2019
Figure 15.65: Opko Health: SWOT Analysis
Figure 15.66: Laboratory Corporation of America Holdings: Portfolio
Figure 15.67: Laboratory Corporation of America Holdings: Overall Financials, 2017-2019
Figure 15.68: Laboratory Corporation of America Holdings: Revenue (by Segment), 2017-2019
Figure 15.69: Laboratory Corporation of America Holdings: Revenue (by Region), 2019
Figure 15.70: Laboratory Corporation of America Holdings: SWOT Analysis
Figure 15.71: OmniSeq: Portfolio
Figure 15.72: OmniSeq: SWOT Analysis
Figure 15.73: Nanostring Technologies: Portfolio
Figure 15.74: Nanostring Technologies: Overall Financials, 2017-2019
Figure 15.75: Nanostring Technologies: Revenue (by Segment), 2017-2019
Figure 15.76: Nanostring Technologies: Revenue (by Region), 2017-2019
Figure 15.77: Nanostring Technologies: SWOT Analysis
Figure 15.78: Guardant Health: Portfolio
Figure 15.79: Guardant Health: Overall Financials, 2017-2019
Figure 15.80: Guardant Health: Revenue (by Segment), 2017-2019
Figure 15.81: Guardant Health: Revenue (by Region), 2017-2019
Figure 15.82: Guardant Health: SWOT Analysis
Figure 15.83: Personal Genome Diagnostics: Portfolio
Figure 15.84: Personal Genome Diagnostics: SWOT Analysis
Figure 15.85: HTG Molecular Diagnostics: Portfolio
Figure 15.86: HTG Molecular Diagnostics: Overall Financials, 2017-2019
Figure 15.87: HTG Molecular Diagnostics: Revenue (by Segment), 2017-2019
Figure 15.88: HTG Molecular Diagnostics: SWOT Analysis
Figure 15.89: Caris Life Sciences: Portfolio
Figure 15.90: Caris Life Sciences: SWOT Analysis
Figure 15.91: Genomic Testing Cooperative: Portfolio
Figure 15.92: Genomic Testing Cooperative: SWOT Analysis
Figure 15.93: ArcherDX, Inc.: Portfolio
Figure 15.94: ArcherDX, Inc.: SWOT Analysis
Figure 1: NCI Fiscal Budget Year on Year, 2013-2018
Figure 2: Impact Analysis of Market Drivers and Market Challenges on the U.S. Solid Tumor Testing Market
Figure 3: U.S. Solid Tumor Testing Market (by Technology), $Million, 2019 and 2030
Figure 4: U.S. Solid Tumor Testing Market (by Cancer Type), $Million, 2019 and 2030
Figure 5: U.S. Solid Tumor Testing Market (by Biomarker Type), $Million, 2019 and 2030
Figure 6: U.S. Solid Tumor Testing Market (by Application), $Million, 2019 and 2030
Figure 7: U.S. Solid Tumor Testing Market (by End User), $Million, 2019 and 2030
Figure 8: Top 5 Contributing States to the U.S. Solid Tumor Testing Market
Figure 2.1: U.S. Solid Tumor Testing Market Segmentation
Figure 3.1: U.S. Solid Tumor Testing Market Research Methodology
Figure 3.2: Primary Research Methodology
Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
Figure 4.1: U.S. Solid Tumor Testing Market 2019-2030
Figure 5.1: Type of Solid Tumors
Figure 5.2: Estimated Percent of New Cancer Cases (by Sex), United States, 2020
Figure 5.3: Expected Cancers Cases in the U.S. (by State), 2020
Figure 5.4: Relative Number of Expected Cancers Cases (by State), 2020
Figure 5.5: Relative Percent of Expected Cancers Cases (by Region), 2020
Figure 5.6: Prevalence of Different Cancers Across the U.S. (2013-2017) *
Figure 7.1: Market Dynamics of U.S. Solid Tumor Testing Market
Figure 7.2: Cancer Cases Projections, 2015-2020
Figure 7.3: Decreasing Cost and Increasing Output (TB) of Genome Sequencing (2009-2025)
Figure 7.4: Synergistic Activities, 2017-2019
Figure 7.5: SBIR and STTR Grants and Contract Funding, 2008-2018
Figure 7.6: NCI Fiscal Budget Year on Year, 2013-2018
Figure 7.7: Reimbursement Cuts Adopted for Oncology Testing, as per PAMA Revisions
Figure 8.1: Share of Key Developments and Strategies, January 2017-December 2019
Figure 8.2: Synergistic Activities Share (by Company), January 2017-December 2019
Figure 8.3: Approvals Share (by Company), January 2017-December 2019
Figure 8.4: Product Launches and Expansion Share (by Company), January 2017-December 2019
Figure 8.5: Acquisitions and Mergers Share (by Company), January 2017-December 2019
Figure 8.6: NCI Budget Allocation, FY2015-FY2018
Figure 8.7: Fund Allocation for Cancer Moonshot Program
Figure 8.8: Market Share Analysis for the U.S. Solid Tumor Testing Market, 2019
Figure 8.9: Growth Share Matrix for U.S. Solid Tumor Testing Market (by Company), 2019
Figure 8.10: Growth Share Matrix for U.S. Solid Tumor Testing Market (by Technology), 2019
Figure 8.11: Growth Share Matrix for U.S. Solid Tumor Testing Market (by Application), 2019
Figure 8.12: Growth Share Matrix for U.S Solid Tumor Testing Market (by Cancer Type), 2019
Figure 9.1: U.S. Solid Tumor Testing Market (by Technology), 2019-2030
Figure 9.2: U.S. Solid Tumor Testing Market (for NGS), 2019-2030
Figure 9.3: U.S. Solid Tumor Testing Market (for Type of NGS Sequencing), 2019-2030
Figure 9.4: U.S. Solid Tumor Testing Market (for ISH), 2019-2030
Figure 9.5: U.S. Solid Tumor Testing Market (for PCR), 2019-2030
Figure 9.6: U.S. Solid Tumor Testing Market (for IHC), 2019-2030
Figure 9.7: U.S. Solid Tumor Testing Market (for Other Technologies), 2019-2030
Figure 10.1: Economic Burden of Major Cancer Types on the U.S. Economy, 2010-2018
Figure 10.2: U.S. Solid Tumor Testing Market (by Cancer Type), 2019-2030
Figure 10.3: Prevalence of Breast Cancer in U.S., 2013-2017
Figure 10.4: U.S. Solid Tumor Testing Market (for Breast Cancer), 2019-2030
Figure 10.5: Total Market Size for U.S. Solid Tumor Testing Market (for Breast Cancer, by Technology), 2019 and 2030
Figure 10.6: Prevalence of Prostate Cancer in U.S., 2013-2017
Figure 10.7: U.S. Solid Tumor Testing Market (for Prostate Cancer), 2019-2030
Figure 10.8: Total Market Size for U.S. Solid Tumor Testing Market (for Prostate Cancer, by Technology), 2019 and 2030
Figure 10.9: Prevalence of Colorectal Cancer in U.S., 2013-2017
Figure 10.10: U.S. Solid Tumor Testing Market (for Colorectal Cancer), 2019-2030
Figure 10.11: Total Market Size for U.S. Solid Tumor Testing Market (for Colorectal Cancer, by Technology), 2019 and 2030
Figure 10.12: Prevalence of Lung Cancer in U.S., 2013-2017
Figure 10.13: U.S. Solid Tumor Testing Market (for Lung Cancer), 2019-2030
Figure 10.14: Total Market Size for U.S. Solid Tumor Testing Market (for Lung Cancer, by Technology), 2019 and 2030
Figure 10.15: Prevalence of Melanoma in U.S., 2013-2017
Figure 10.16: U.S. Solid Tumor Testing Market (for Melanoma), 2019-2030
Figure 10.17: Total Market Size for U.S. Solid Tumor Testing Market (for Melanoma, by Technology), 2019 and 2030
Figure 10.18: Prevalence of Endometrial Cancer in U.S., 2013-2017
Figure 10.19: U.S. Solid Tumor Testing Market (for Endometrial Cancer), 2019-2030
Figure 10.20: Total Market Size for U.S. Solid Tumor Testing Market (for Endometrial Cancer, by Technology), 2019 and 2030
Figure 10.21: Prevalence of Thyroid Cancer in U.S., 2013-2017
Figure 10.22: U.S. Solid Tumor Testing Market (for Thyroid Cancer), 2019-2030
Figure 10.23: Total Market Size for U.S. Solid Tumor Testing Market (for Thyroid Cancer, by Technology), 2019 and 2030
Figure 10.24: Prevalence of Brain Cancer in U.S., 2013-2017
Figure 10.25: U.S. Solid Tumor Testing Market (for Brain Cancer), 2019-2030
Figure 10.26: Total Market Size for U.S. Solid Tumor Testing Market (for Brain Cancer, by Technology), 2019 and 2030
Figure 10.27: Prevalence of Ovarian Cancer in U.S., 2013-2017
Figure 10.28: U.S. Solid Tumor Testing Market (for Ovarian Cancer), 2019-2030
Figure 10.29: Total Market Size for U.S. Solid Tumor Testing Market (for Ovarian Cancer, by Technology), 2019 and 2030
Figure 10.30: Prevalence of Liver Cancer in U.S., 2013-2017
Figure 10.31: U.S. Solid Tumor Testing Market (for Liver Cancer), 2019-2030
Figure 10.32: Total Market Size for U.S. Solid Tumor Testing Market (for Liver Cancer, by Technology), 2019 and 2030
Figure 10.33: U.S. Solid Tumor Testing Market (for Other Cancer Types), 2019-2030
Figure 10.34: Total Market Size for U.S. Solid Tumor Testing Market (for Other Cancer Types, by Technology), 2019 and 2030
Figure 11.1: U.S. Solid Tumor Testing Market (by Type of Biomarker), 2019-2030
Figure 11.2: Technologies and Data Types for Genetic Biomarker Discovery
Figure 11.3: U.S. Solid Tumor Testing Market (for Genetic Biomarkers), 2019-2030
Figure 11.4: Technologies and Data Types for Protein Biomarker Discovery
Figure 11.5: U.S. Solid Tumor Testing Market (for Protein Biomarkers), 2019-2030
Figure 11.6: U.S. Solid Tumor Testing Market (for Other Biomarkers), 2019-2030
Figure 12.1: U.S. Solid Tumor Testing Market (by Application), 2019-2030
Figure 12.2: U.S. Solid Tumor Testing Market (for Clinical Applications), 2019-2030
Figure 12.3: U.S. Solid Tumor Testing Market (for Types of Clinical Applications), 2019-2030
Figure 12.4: U.S. Solid Tumor Testing Market (for Research Applications), 2019-2030
Figure 12.5: U.S. Solid Tumor Testing Market (for Types of Research Applications), 2019-2030
Figure 13.1: U.S. Solid Tumor Testing Market (by End User), 2019-2030
Figure 13.2: U.S. Solid Tumor Testing Market (for Hospitals, Diagnostic Laboratories, and Reference Laboratories), 2019-2030
Figure 13.3: U.S. Solid Tumor Testing Market (for Pharmaceutical and Biotechnology Companies), 2019-2030
Figure 13.4: U.S. Solid Tumor Testing Market (for Contract Research Organization), 2019-2030
Figure 13.5: U.S. Solid Tumor Testing Market (for Academic Research Institutions), 2019-2030
Figure 13.6: U.S. Solid Tumor Testing Market (for Other End Users), 2019-2030
Figure 14.1: U.S. Solid Tumor Testing Market (by State Region), 2019-2030
Figure 14.2: Growth in Top 5 States in the U.S. Solid Tumor Testing Market, 2019-2030
Figure 14.3: The South U.S. Solid Tumor Testing Market, 2019-2030
Figure 14.4: The South U.S. Solid Tumor Testing Market (by State), 2019, 2025, and 2030
Figure 14.5: The Midwest U.S. Solid Tumor Testing Market, 2019-2030
Figure 14.6: The Midwest U.S. Solid Tumor Testing Market (by State), 2019, 2025, and 2030
Figure 14.7: The Mid-Atlantic U.S. Solid Tumor Testing Market, 2019-2030
Figure 14.8: The Mid-Atlantic U.S. Solid Tumor Testing Market (by State), 2019, 2025, and 2030
Figure 14.9: The West U.S. Solid Tumor Testing Market, 2019-2030
Figure 14.10: The West U.S. Solid Tumor Testing Market (by State), 2019, 2025, and 2030
Figure 14.11: The Southwest U.S. Solid Tumor Testing Market, 2019-2030
Figure 14.12: The Southwest U.S. Solid Tumor Testing Market (by State), 2019, 2025, and 2030
Figure 14.13: New England Solid Tumor Testing Market, 2019-2030
Figure 15.1: Total Number of Companies Profiled
Figure 15.2: Abbott Laboratories: Portfolio
Figure 15.3: Abbott Laboratories: Overall Financials, 2017-2019
Figure 15.4: Abbott Laboratories: Revenue (by Segment), 2017-2019
Figure 15.5: Abbott Laboratories: Revenue Split for Diagnostics, 2017-2019
Figure 15.6: Abbott Laboratories: Revenue (by Region), 2017-2019
Figure 15.7: Abbott Laboratories: R&D Expenditure, 2017-2019
Figure 15.8: Abbott Laboratories: SWOT Analysis
Figure 15.9: Illumina, Inc.: Portfolio
Figure 15.10: Illumina, Inc.: Overall Financials, 2017-2019
Figure 15.11: Illumina, Inc.: Revenue (by Segment), 2017-2019
Figure 15.12: Illumina, Inc.: Revenue (by Region), 2017-2019
Figure 15.13: Illumina, Inc.: R&D Expenditure, 2017-2019
Figure 15.14: Illumina, Inc.: SWOT Analysis
Figure 15.15: F. Hoffmann-La Roche Ltd: Portfolio
Figure 15.16: F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019
Figure 15.17: F. Hoffmann-La Roche Ltd: Sales (by Segment), 2017-2019
Figure 15.18: F. Hoffmann-La Roche Ltd: Sales (by Region), 2017-2019
Figure 15.19: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2017-2019
Figure 15.20: F. Hoffmann-La Roche: SWOT Analysis
Figure 15.21: Bio-Rad Laboratories, Inc.: Portfolio
Figure 15.22: Bio-Rad Laboratories, Inc.: Overall Financials, 2017-2019
Figure 15.23: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2017-2019
Figure 15.24: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2017-2019
Figure 15.25: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2017-2019
Figure 15.26: Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 15.27: ASURAGEN, INC.: Portfolio
Figure 15.28: ASURAGEN, INC.: SWOT Analysis
Figure 15.29: Cancer Genetics Inc.: Portfolio
Figure 15.30: Cancer Genetics Inc.: Overall Financials, 2016-2018
Figure 15.31: Cancer Genetics Inc.: Sales (by Segment), 2016-2018
Figure 15.32: Cancer Genetics Inc.: Sales (by Region), 2016-2018
Figure 15.33: Cancer Genetics Inc.: R&D Expenditure, 2016-2018
Figure 15.34: Cancer Genetics Inc.: SWOT Analysis
Figure 15.35: QIAGEN N.V.: Portfolio
Figure 15.36: QIAGEN N.V.: Overall Financials, 2017-2019
Figure 15.37: QIAGEN N.V.: Revenue (by Segment), 2017-2019
Figure 15.38: QIAGEN N.V.: Revenue (by Region), 2017-2019
Figure 15.39: QIAGEN N.V.: R&D Expenditure, 2017-2019
Figure 15.40: QIAGEN N.V.: SWOT Analysis
Figure 15.41: Quest Diagnostics Incorporated: Portfolio
Figure 15.42: Quest Diagnostics Incorporated: Overall Financials, 2017-2019
Figure 15.43: Quest Diagnostics Incorporated: Revenue (by Business Segment), 2017-2019
Figure 15.44: Quest Diagnostics Incorporated: SWOT Analysis
Figure 15.45: ARUP Laboratories: Portfolio
Figure 15.46: ARUP Laboratories: SWOT Analysis
Figure 15.47: Invivoscribe, Inc.: Portfolio
Figure 15.48: Invivoscribe, Inc.: SWOT Analysis
Figure 15.49: NeoGenomics Laboratories, Inc.: Portfolio
Figure 15.50: NeoGenomics Laboratories, Inc.: Overall Financials, 2017-2019
Figure 15.51: NeoGenomics Laboratories, Inc.: Revenue (by Segment), 2017-2019
Figure 15.52: NeoGenomics Laboratories, Inc.: R&D Expenditure, 2017-2019
Figure 15.53: NeoGenomics Laboratories, Inc.: SWOT Analysis
Figure 15.54: Invitae Corporation: Portfolio
Figure 15.55: Invitae Corporation: Overall Financials, 2017-2019
Figure 15.56: Invitae Corporation: Revenue (by Segment), 2017-2019
Figure 15.57: Invitae Corporation: Revenue (by Geography), 2017-2019
Figure 15.58: Invitae Corporation: R&D Expenditure, 2017-2019
Figure 15.59: Invitae Corporation: SWOT Analysis
Figure 15.60: Opko Health: Portfolio
Figure 15.61: Opko Health: Overall Financials, 2017-2019
Figure 15.62: Opko Health: Revenue (by Segment), 2017-2019
Figure 15.63: Opko Health: Revenue (by Region), 2017-2019
Figure 15.64: Opko Health: R&D Expenditure, 2017-2019
Figure 15.65: Opko Health: SWOT Analysis
Figure 15.66: Laboratory Corporation of America Holdings: Portfolio
Figure 15.67: Laboratory Corporation of America Holdings: Overall Financials, 2017-2019
Figure 15.68: Laboratory Corporation of America Holdings: Revenue (by Segment), 2017-2019
Figure 15.69: Laboratory Corporation of America Holdings: Revenue (by Region), 2019
Figure 15.70: Laboratory Corporation of America Holdings: SWOT Analysis
Figure 15.71: OmniSeq: Portfolio
Figure 15.72: OmniSeq: SWOT Analysis
Figure 15.73: Nanostring Technologies: Portfolio
Figure 15.74: Nanostring Technologies: Overall Financials, 2017-2019
Figure 15.75: Nanostring Technologies: Revenue (by Segment), 2017-2019
Figure 15.76: Nanostring Technologies: Revenue (by Region), 2017-2019
Figure 15.77: Nanostring Technologies: SWOT Analysis
Figure 15.78: Guardant Health: Portfolio
Figure 15.79: Guardant Health: Overall Financials, 2017-2019
Figure 15.80: Guardant Health: Revenue (by Segment), 2017-2019
Figure 15.81: Guardant Health: Revenue (by Region), 2017-2019
Figure 15.82: Guardant Health: SWOT Analysis
Figure 15.83: Personal Genome Diagnostics: Portfolio
Figure 15.84: Personal Genome Diagnostics: SWOT Analysis
Figure 15.85: HTG Molecular Diagnostics: Portfolio
Figure 15.86: HTG Molecular Diagnostics: Overall Financials, 2017-2019
Figure 15.87: HTG Molecular Diagnostics: Revenue (by Segment), 2017-2019
Figure 15.88: HTG Molecular Diagnostics: SWOT Analysis
Figure 15.89: Caris Life Sciences: Portfolio
Figure 15.90: Caris Life Sciences: SWOT Analysis
Figure 15.91: Genomic Testing Cooperative: Portfolio
Figure 15.92: Genomic Testing Cooperative: SWOT Analysis
Figure 15.93: ArcherDX, Inc.: Portfolio
Figure 15.94: ArcherDX, Inc.: SWOT Analysis
